Abstract
Nucleophosmin (NPM1) is a protein of highly conserved nature which works as a molecular chaperone and is mostly found in nucleoli. NPM also involved in the maturation of preribosomes and duplication of centrosomes. Furthermore, it is also active in control and regulation of the ARF-p53 tumor suppressor pathway. A high rate of incidence and prognostic involvement is reported by various authors in AML patients. In AML it behaves as a favorable prognostic marker. NPM mutations are more frequently associated with normal-karyotype AML and are usually absent in patients having abnormal or poor cytogenetic. NPM mutations are not frequent in other hematopoietic tumors .Two main types of mutations have been described to date. Both of these cause abnormal cytoplasmic localization of NPM1. Their high incidence rate in normal karyoptype and their favorable nature make those mutations hot spot or front face mutations which should be checked before treatment starts.
Highlights
In World Health Organization 2008, AML with mutated NPM have assigned a separate class of myeloid nucleoplasm which have unique molecular, prognostic and pathological feature (Michael et al, 2010)
Nucleophosmin (NPM1) is a protein of highly conserved nature which works as a molecular chaperone and is mostly found in nucleoli
All patients with NPM1 mutations are alive in remission, A comparison of the age of the adult patients with type A and non-type A mutations indicated that patients with type A mutations had a trend for a higher median age (60 years), compared to cases with non-A mutations
Summary
In World Health Organization 2008, AML with mutated NPM have assigned a separate class of myeloid nucleoplasm which have unique molecular, prognostic and pathological feature (Michael et al, 2010). Various authors attribute mutated NPM as favorable prognostic marker for Overall survival or event free survival in AML having AML_NK. This attribution makes NPM an important candidate to study for the better understanding of leukemogenesis
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
